茚地那韦在感染人类免疫缺陷病毒的孕妇中的药代动力学及安全性
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
作者信息
Unadkat Jashvant D, Wara Diane W, Hughes Michael D, Mathias Anita A, Holland Diane T, Paul Mary E, Connor James, Huang Sharon, Nguyen Bach-Yen, Watts D Heather, Mofenson Lynne M, Smith Elizabeth, Deutsch Paul, Kaiser Kathleen A, Tuomala Ruth E
机构信息
Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA.
出版信息
Antimicrob Agents Chemother. 2007 Feb;51(2):783-6. doi: 10.1128/AAC.00420-06. Epub 2006 Dec 11.
Abstract
Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.
摘要
16名感染人类免疫缺陷病毒的女性在妊娠14至28周期间至产后12周接受茚地那韦（每日三次，每次800毫克）加齐多夫定加拉米夫定治疗。两名女性和八名婴儿出现了可能与治疗相关的3级或4级毒性反应。与产后相比，茚地那韦的血浆浓度-时间曲线下面积在产前降低了68%，提示孕期肠道和/或肝脏CYP3A活性增加。
相似文献
1
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.茚地那韦在感染人类免疫缺陷病毒的孕妇中的药代动力学及安全性
Antimicrob Agents Chemother. 2007 Feb;51(2):783-6. doi: 10.1128/AAC.00420-06. Epub 2006 Dec 11.
2
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.一项针对人类免疫缺陷病毒感染且每立方毫米CD4细胞计数为200或更低的患者，使用两种核苷类似物加茚地那韦的对照试验。艾滋病临床试验组320研究团队。
N Engl J Med. 1997 Sep 11;337(11):725-33. doi: 10.1056/NEJM199709113371101.
3
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.依非韦伦加齐多夫定和拉米夫定、依非韦伦加茚地那韦以及茚地那韦加齐多夫定和拉米夫定用于治疗成人HIV-1感染。006研究团队。
N Engl J Med. 1999 Dec 16;341(25):1865-73. doi: 10.1056/NEJM199912163412501.
4
Differential bidirectional transfer of indinavir in the isolated perfused human placenta.茚地那韦在离体灌注人胎盘中的差异双向转运
Antimicrob Agents Chemother. 2005 Mar;49(3):1023-8. doi: 10.1128/AAC.49.3.1023-1028.2005.
5
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.阿凡提2. 一项随机、双盲试验，旨在评估齐多夫定加拉米夫定与齐多夫定加拉米夫定加茚地那韦在未接受过抗逆转录病毒治疗的HIV感染患者中的疗效和安全性。
AIDS. 2000 Mar 10;14(4):367-74.
6
Pharmacokinetics of indinavir in HIV-positive pregnant women.茚地那韦在HIV阳性孕妇中的药代动力学。
AIDS. 2000 May 26;14(8):1061-2. doi: 10.1097/00002030-200005260-00020.
7
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.蛋白酶抑制剂茚地那韦在1型人类免疫缺陷病毒感染儿童中的药代动力学。
Antimicrob Agents Chemother. 2001 Mar;45(3):701-5. doi: 10.1128/AAC.45.3.701-705.2001.
8
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.药物遗传学对开始高效抗逆转录病毒治疗（HAART）的HIV患者茚地那韦处置及短期反应的影响。
Eur J Clin Pharmacol. 2009 Jul;65(7):667-78. doi: 10.1007/s00228-009-0660-5. Epub 2009 May 14.
9
Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women.沙奎那韦-SGC在HIV感染孕妇中的药代动力学。
HIV Clin Trials. 2001 Nov-Dec;2(6):460-5. doi: 10.1310/PUY3-5JWL-FX2B-98VU.
10
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.齐多夫定治疗降低母婴1型人类免疫缺陷病毒传播。儿童艾滋病临床试验组方案076研究小组。
N Engl J Med. 1994 Nov 3;331(18):1173-80. doi: 10.1056/NEJM199411033311801.
引用本文的文献
1
The effect of pregnancy-related hormones on hepatic transporters: studies with premenopausal human hepatocytes.妊娠相关激素对肝脏转运体的影响：绝经前人类肝细胞的研究
Front Pharmacol. 2024 Aug 7;15:1440010. doi: 10.3389/fphar.2024.1440010. eCollection 2024.
2
Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity.妊娠和维生素 A 补充对 CYP2D6 活性的影响。
J Clin Pharmacol. 2023 Mar;63(3):363-372. doi: 10.1002/jcph.2169. Epub 2022 Nov 15.
3
Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.整合生理药代动力学模型和人胎盘灌注实验预测地瑞那韦在母体和胎儿的暴露量。
Clin Pharmacokinet. 2022 Aug;61(8):1129-1141. doi: 10.1007/s40262-022-01127-0. Epub 2022 May 17.
4
Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy.基于生理的药代动力学模型在舍曲林孕期给药推荐中的应用。
NPJ Syst Biol Appl. 2020 Nov 6;6(1):36. doi: 10.1038/s41540-020-00157-3.
5
Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?抗逆转录病毒药物在 HIV 感染孕妇中的药物相互作用：与非孕妇有何不同？
Clin Pharmacokinet. 2020 Oct;59(10):1217-1236. doi: 10.1007/s40262-020-00914-x.
6
Mechanisms of CYP3A Induction During Pregnancy: Studies in HepaRG Cells.妊娠期 CYP3A 诱导的机制：HepaRG 细胞研究。
AAPS J. 2019 Mar 27;21(3):45. doi: 10.1208/s12248-019-0316-z.
7
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.妊娠相关的药代动力学变化：一项系统评价。
PLoS Med. 2016 Nov 1;13(11):e1002160. doi: 10.1371/journal.pmed.1002160. eCollection 2016 Nov.
8
Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS.采用液相色谱-串联质谱法对孕妇血浆和尿液中的普伐他汀及其代谢产物3α-羟基普伐他汀进行定量测定。
Biomed Chromatogr. 2016 Apr;30(4):548-54. doi: 10.1002/bmc.3581. Epub 2015 Sep 11.
9
Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.基于HepaRG细胞和人肝细胞预测体内肝脏CYP3A活性的孕龄依赖性诱导
Drug Metab Dispos. 2015 Jun;43(6):836-42. doi: 10.1124/dmd.114.062984. Epub 2015 Mar 23.
10
Pituitary and brain dopamine D2 receptors regulate liver gene sexual dimorphism.垂体和脑多巴胺D2受体调节肝脏基因的性二态性。
Endocrinology. 2015 Mar;156(3):1040-51. doi: 10.1210/en.2014-1714. Epub 2014 Dec 29.
本文引用的文献
1
Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein.孕期抗HIV蛋白酶抑制剂的药代动力学变化：细胞色素P450 3A和P-糖蛋白的作用
J Pharmacol Exp Ther. 2006 Mar;316(3):1202-9. doi: 10.1124/jpet.105.095406. Epub 2005 Nov 17.
2
Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.孕期药物代谢（CYP1A2、CYP2D6和CYP3A活性）的时间变化。
Am J Obstet Gynecol. 2005 Feb;192(2):633-9. doi: 10.1016/j.ajog.2004.08.030.
3
Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view.从临床医生角度看：利用抗逆转录病毒血浆药物水平监测改善HIV感染管理
Curr HIV Res. 2004 Oct;2(4):309-21. doi: 10.2174/1570162043351129.
4
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).在初治成人抗逆转录病毒治疗中，与茚地那韦/拉米夫定/齐多夫定复方片剂（COM）相比，阿巴卡韦联合拉米夫定/齐多夫定复方片剂进行三联核苷治疗：一项48周开放标签等效性试验（CNA3014）的结果
Curr Med Res Opin. 2004 Jul;20(7):1103-14. doi: 10.1185/030079904125004006.
5
Therapeutic drug monitoring in HIV infection: current status and future directions.HIV感染中的治疗药物监测：现状与未来方向。
AIDS. 2002 Mar;16 Suppl 1:S5-37. doi: 10.1097/00002030-200203001-00002.
6
Physiologic changes in pregnancy and their effect on drug disposition.妊娠期的生理变化及其对药物处置的影响。
Semin Perinatol. 2001 Jun;25(3):120-3. doi: 10.1053/sper.2001.24565.
7
HIV's pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics.人类免疫缺陷病毒的药代动力学、药效动力学、药物遗传学和药物基因组学。
Am Clin Lab. 2000 Nov-Dec;19(9):12.
8
9
Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention.美国公共卫生服务工作组关于在感染HIV-1的孕妇中使用抗逆转录病毒药物以保障孕产妇健康和减少围产期HIV-1传播的建议。疾病控制与预防中心。
MMWR Recomm Rep. 1998 Jan 30;47(RR-2):1-30.
10
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.齐多夫定治疗降低母婴1型人类免疫缺陷病毒传播。儿童艾滋病临床试验组方案076研究小组。
N Engl J Med. 1994 Nov 3;331(18):1173-80. doi: 10.1056/NEJM199411033311801.
Zotero 插件